CRISPR/Cas9-induced saturated mutagenesis identifies Rad51 haplotype as a marker of PARP inhibitor sensitivity in breast cancer

Breast cancer treatment with poly(ADP-ribose)polymerase (PARP) inhibitors is currently limited to cells defective in the homologous recombination repair (HRR) pathway. The chemical inhibition of many HRR deficiency genes may sensitize cancer cells to PARP inhibitors. In the present study, Rad51, a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hua, Wei, Yaning, Zhang, Qian, Yang, Yang, Bi, Xuebing, Yang, Lin, Xiao, Na, Zang, Aimin, Ren, Lili, Li, Xiaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309539/
https://www.ncbi.nlm.nih.gov/pubmed/35713220
http://dx.doi.org/10.3892/mmr.2022.12774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309539/
https://www.ncbi.nlm.nih.gov/pubmed/35713220
http://dx.doi.org/10.3892/mmr.2022.12774

Ejemplares similares